Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in côte d'ivoire

Journal of Infectious Diseases

Volumn 209, Issue 3, 2014, Pages 431-440

  Jean, Kévin ^a   Gabillard, Delphine ^b,d   Moh, Raoul ^d   Danel, Christine ^d   Fassassi, Raïmi ^e   Desgrées Du Loû, Annabel ^c   Eholié, Serge ^d   Lert, France ^a   Anglaret, Xavier ^b,d   Dray Spira, Rosemary ^a  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b INSERM   (France)

^c Inserm   (France)

^d CHU de Treichville   (France)

^e Department of Population Research and Development   (Morocco)

Author keywords

antiretroviral treatment; epidemiology; HIV prevention; HIV 1 sexual transmission; sexual behaviors; sub Saharan Africa; treatment as prevention

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COTE D'IVOIRE; EARLY INTERVENTION; FEMALE; HEALTH STATUS; HETEROSEXUALITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; TREATMENT RESPONSE; TUBERCULOSIS; UNPROTECTED SEX; VIRUS LOAD; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTIRETROVIRAL TREATMENT; EPIDEMIOLOGY; HIV PREVENTION; HIV-1 SEXUAL TRANSMISSION; SEXUAL BEHAVIORS; SUB-SAHARAN AFRICA; TREATMENT AS PREVENTION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COTE D'IVOIRE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RISK FACTORS; SEXUAL BEHAVIOR;

EID: 84892660523     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit470     Document Type: Article

References (38)

1. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
2. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bull Med Suisse 2008; 89:5, pp165-169.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
4. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
5. Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012; 9:e1001245.
6. Dabis F. Reality check: is the end of AIDS in sight? In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2013.
7. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS Lond Engl 2001; 15:369-78.
8. Tun W, Gange SJ, Vlahov D, Strathdee SA, Celentano DD. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users. Clin Infect Dis Off Publ Infect Dis Soc Am 2004; 38:1167-74.
9. Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006; 332:605-7.
10. Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007; 4:165-72.
11. Venkatesh KK, Flanigan TP, Mayer KH. Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world. AIDS Lond Engl 2011; 25:1939-49.
12. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis Off Publ Infect Dis Soc Am 2010; 50(Suppl 3):S85-95.
13. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292: 224-36.
14. The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV treatment as prevention: models, data, and questions-towards evidence-based decision-making. PLoS Med 2012; 9: e1001259.
15. Guidance on couples HIV testing and counseling including antiretroviral therapy for treatment as prevention in serodiscordant couples. Geneva: World Health Organization, 2012. http://www.who.int/hiv/pub/guidelines/9789241501972/ en/. Accessed 11 September 2013.
16. Chemaitelly H, Shelton JD, Hallett TB, Abu-Raddad LJ. Only a fraction of new HIV infections occur within identifiable stable discordant couples in sub-Saharan Africa. AIDS 2013; 27:251-60.
17. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2006 revision. Geneva: World Health Organization, 2006. http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf. Accessed 11 September 2013.
18. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. Geneva: World Health Organization, 2010. http://www.who.int/hiv/pub/arv/adult2010/en/index. html. Accessed 11 September 2013.
19. Hughes JP, Baeten JM, Lingappa JR., et al. Determinants of per-coitalact HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 2012; 205:358-65.
20. Institut National de la Statistique (INS) & Ministère de la Lutte contre le Sida [Côte d'Ivoire] & ORC Macro. AIDS Indicators Survey, Côte d'Ivoire 2005. Calverton, MD: INS & ORC Macro, 2006.
21. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372:314-20.
22. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-53.
23. Moatti J-P, Prudhomme J, Traore DC, Juillet-Amari A, Akribi HA-D, Msellati P. Access to antiretroviral treatment and sexual behaviours of HIV-infected patients aware of their serostatus in Côte d'Ivoire. AIDS Lond Engl 2003; 17(Suppl 3):S69-77.
24. Diabaté S, Alary M, Koffi CK. Short-term increase in unsafe sexual behaviour after initiation of HAART in Côte d'Ivoire. AIDS Lond Engl 2008; 22:154-6.
25. Protopopescu C, Marcellin F, Préau M, et al. Psychosocial correlates of inconsistent condom use among HIV-infected patients enrolled in a structured ART interruptions trial in Côte d'Ivoire: results from the TRIVACAN trial (ANRS 1269). Trop Med Int Heal TM IH 2010; 15:706-712.
26. Sarna A, Luchters SMF, Geibel S, et al. Sexual risk behaviour and HAART: a comparative study of HIV-infected persons on HAART and on preventive therapy in Kenya. Int J STD AIDS 2008; 19:85-9.
27. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011; 8:e1001056.
28. Wamoyi J, Mbonye M, Seeley J, Birungi J, Jaffar S. Changes in sexual desires and behaviours of people living with HIV after initiation of ART: Implications for HIV prevention and health promotion. BMC Public Health 2011; 11:633.
29. Apondi R, Bunnell R, Ekwaru JP, et al. Sexual behavior and HIV transmission risk of Ugandan adults taking antiretroviral therapy: 3 year follow-up. AIDS Lond Engl 2011; 25:1317-27.
30. Baggaley RF, White RG, Hollingsworth TD, Boily M-C. Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. Epidemiology 2013; 24:110-21.
31. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 Serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8:e1001123.
32. Jean K, Anglaret X, Moh R, Lert F, Dray-Spira R. Barriers to HIV Testing in Côte d'Ivoire: The Role of Individual Characteristics and Testing Modalities. PLoS ONE 2012; 7:e41353.
33. Barth RE, van der Loeff MFS, Schuurman R, Hoepelman AIM, Wensing AMJ. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-66.
34. Moh R, Danel C, Badje A, et al. Conséquences des conflits armés sur la prise en charge des personnes infectées par le VIH: exemple de l'essai Temprano (ANRS 12136). In: AFRAVIH 2012-6ème Conférence Francophone VIH/SIDA, Geneva, Switzerland, 26 March 2012.
35. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell M-L. High coverage of ART associated with decline in risk of HIV acquisition in Rural KwaZulu-Natal, South Africa. Science 2013; 339:966-71.
36. Wilson DP. HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med 2012; 9:e1001231.
37. Delva W, Eaton JW, Meng F, et al. HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes. PLoS Med 2012; 9:e1001258.
38. Bellan SE, Fiorella KJ, Melesse DY, Getz WM, Williams BG, Dushoff J. Extra-couple HIV transmission in sub-Saharan Africa: a mathematical modelling study of survey data. Lancet 2013; 381:1561-9.